Nursing care
Opioid agonist-antagonists in labour: ceiling effect, withdrawal risk and newborn checks
Written and reviewed by Dana Whitfield, RN, MSN · 4 min read · Updated October 2026
Short answer
Butorphanol and nalbuphine stimulate kappa opioid receptors while partly blocking or only weakly activating mu receptors. That mix gives labour analgesia with a ceiling on respiratory depression, but it can trigger withdrawal in a patient dependent on opioids. The nurse monitors maternal sedation and breathing, the fetal heart rate, and the newborn's respiratory effort after birth.
How the mixed receptor profile works
Nalbuphine acts as a kappa receptor agonist and a mu receptor antagonist. Butorphanol is a full kappa agonist and a partial mu agonist. Kappa activity provides much of the pain relief and sedation, while the limited mu effect explains why the drugs behave differently from morphine or fentanyl, both in benefit and in risk.
The labels describe a ceiling effect: above a certain dose, respiratory depression does not keep deepening as it would with a full mu agonist, although with butorphanol its duration can lengthen. This is not immunity. Combined sedatives such as benzodiazepines, other depressants or a sensitive patient can still produce dangerous respiratory depression, which is why the boxed warnings apply.
Precipitated withdrawal in opioid-dependent patients
Because these drugs block or only partly stimulate mu receptors, giving them to someone physically dependent on opioids can displace the full agonist and cause abrupt withdrawal. Both labels warn about this and advise avoiding use with full agonist analgesics. In pregnancy, this includes people taking methadone or buprenorphine for opioid use disorder, or those using opioids illicitly.
Before giving butorphanol or nalbuphine, the nurse reviews the medication history and substance use screening. If dependence is known or suspected, the nurse holds the dose and clarifies the order. Signs of precipitated withdrawal include agitation, sweating, yawning, tearing, nausea, cramps and a sudden rise in pain. Sudden withdrawal in pregnancy is a fetal concern too.
Maternal and fetal monitoring after a dose
Sedation and dizziness are the most frequent adverse effects in the labels, so the nurse checks level of consciousness, respiratory rate and oxygen saturation, keeps the bed low and assists with walking. Butorphanol can increase cardiac workload and has rare reports of severe hypertension, so blood pressure is part of the reassessment rather than an afterthought.
The fetus is monitored as well. The butorphanol label describes transient sinusoidal fetal heart rate patterns, and the nalbuphine label reports fetal bradycardia, some of it severe and prolonged. The nurse reviews the tracing before giving the dose and watches it closely afterwards, reporting new bradycardia, reduced variability or an abnormal pattern according to protocol.
Newborn respiratory checks and naloxone
These drugs cross the placenta. Labels report neonatal respiratory depression, apnoea, cyanosis and hypotonia, particularly when a dose is given close to delivery. The nurse communicates the drug name and time of the last dose to the birth team so the newborn can be observed for breathing effort, tone, colour and heart rate from the first minute.
Naloxone can reverse the respiratory depression, although larger doses may be needed for butorphanol and its effect may wear off before the opioid's does, so observation continues afterwards. The butorphanol label also warns that prolonged opioid use in pregnancy can cause neonatal opioid withdrawal syndrome, so the newborn team needs the full maternal medication history, not just the labour dose.
Working a hypothetical labour scenario
Imagine a labouring patient who requests pain relief and has butorphanol prescribed. During admission she mentioned taking a daily prescribed medicine for opioid use disorder. The options are to give the butorphanol now, give half the dose to reduce sedation, hold the dose and contact the prescriber, or offer butorphanol with an antiemetic.
Holding the dose and contacting the prescriber is the best response, because an agonist-antagonist can precipitate withdrawal in a person dependent on opioids. A smaller dose does not remove that risk, and an antiemetic addresses only one symptom. The prescriber can choose another analgesic plan, such as neuraxial options. This is an invented study example.
Sources and further reading
DailyMed: Nalbuphine hydrochloride injection prescribing information. Kappa agonist and mu antagonist action, respiratory ceiling effect, precipitated withdrawal, fetal bradycardia, neonatal respiratory depression and naloxone reversal.
DailyMed: Butorphanol tartrate injection prescribing information. Partial mu and full kappa agonist action, withdrawal with full agonists, sinusoidal fetal heart rate pattern, neonatal apnoea, sedation, cardiac workload and naloxone dosing caveats.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our maternity and newborn practice questions are the closest set to what this page covers.
Common questions
Does the ceiling effect mean nalbuphine cannot cause respiratory depression?
No. Respiratory depression still occurs and can be serious, especially with benzodiazepines or other depressants. The ceiling only means it does not keep deepening with higher doses as it does with full agonists.
Why should butorphanol be avoided in a patient on methadone?
Its mu antagonist effect can displace methadone from receptors and precipitate sudden withdrawal. The nurse holds the dose and asks the prescriber for an alternative.
What newborn findings should the nurse report after maternal butorphanol or nalbuphine?
Weak or absent breathing, apnoea, cyanosis, poor tone or a low heart rate. The birth team needs the drug name and time of the last maternal dose.